Immunotherapy, as exemplified by immune checkpoint inhibitors (ICIs) such as PD-1–blocking antibodies, has become the standard of care for a wide variety of cancer types, and the immunological profile of the tumor microenvironment (TME) is becoming increasingly important to optimize combination treatment with ICIs (1, 2). The gene discussed is PDCD1; the disease is neoplasm.